Regeneron Pharmaceuticals Inc. (REGN)

298.37
0.17 0.06
NASDAQ : Health Technology
Prev Close 298.20
Open 299.19
Day Low/High 295.78 / 299.69
52 Wk Low/High 287.66 / 442.00
Volume 492.34K
Avg Volume 898.20K
Exchange NASDAQ
Shares Outstanding 107.73M
Market Cap 32.08B
EPS 22.60
P/E Ratio 13.85
Div & Yield N.A. (N.A)

Regeneron Cut to Underperform at Baird

Cramer: Rotations Hit Companies That Don't Deserve It

Cramer: Rotations Hit Companies That Don't Deserve It

Case in point: Home Depot and Lowe's.

Cramer: Stop Talking About the 'Market'

Cramer: Stop Talking About the 'Market'

It just isn't as useful or descriptive right now.

Cramer: This Is No Country for Old Value

Cramer: This Is No Country for Old Value

Down-and-out stocks have become toxic.

Cramer: You Need 2 Monday Morning Game Plans

Cramer: You Need 2 Monday Morning Game Plans

We really want to shake out the weak hands here.

Cramer: Rally Is Earning Some Trust

Cramer: Rally Is Earning Some Trust

The market rally broadened out nicely today.

Charting the Biotechs

Charting the Biotechs

Time to revisit some stocks now that biotech has cooled.

Regeneron Shows Green Shoots

Regeneron Shows Green Shoots

Clues in the chart point to higher prices to come.

Cramer: Retail Rally Shows the Perils of Being Too Negative

Cramer: Retail Rally Shows the Perils of Being Too Negative

There's a forest fire in the sector.

Regeneron Is Ready to Rally

Regeneron Is Ready to Rally

An upside breakout appears on the horizon.

Regeneron Could Generate More Upside

Regeneron Could Generate More Upside

Dips in the pharma name have been bought, a sign of demand that presents a relatively low-risk buying opportunity.

Regeneron Is Ready to Reanimate: Watch for a Breakout

Regeneron Is Ready to Reanimate: Watch for a Breakout

This stock is testing resistance and could push back up to last year's highs.

Cramer: Don't Give the Fed Credit

Cramer: Don't Give the Fed Credit

Most of the 10 best stocks of the bull market did it their way.

Cramer: When a Trump Tweet Is a Buy Signal

Cramer: When a Trump Tweet Is a Buy Signal

Drug companies are the latest targets/beneficiaries.

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.

Cramer: Buyers for Bristol-Myers Are Few and Far Between

Cramer: Buyers for Bristol-Myers Are Few and Far Between

Icahn may have a tough time finding interest in this behemoth.

Amgen Shows a Bullish Breakout

Amgen Shows a Bullish Breakout

There is more upside to come for this stock.

Bullish Momentum for Regeneron

Bullish Momentum for Regeneron

Volatility has calmed down, and there are bullish signs.

Regeneron upgraded at Piper

Cramer: Here's the Reason for Allergan's Remarkable Run

Cramer: Here's the Reason for Allergan's Remarkable Run

Static doesn't work in this industry. Pipelines work.

Closing Bell: Active Oil Rigs Rise; Dow Gets Close to 20K but Falls Short

Closing Bell: Active Oil Rigs Rise; Dow Gets Close to 20K but Falls Short

The Dow Jones Industrial Average came agonizingly close to its 20,000 milestone before falling short and backing off.

Jim Cramer Sees Buying Opportunities in Praluent Patent Suit

Jim Cramer Sees Buying Opportunities in Praluent Patent Suit

After a court halts Regeneron's sales of Praluent, Jim Cramer sees opportunity in Amgen.

Use Regeneron's Current Weakness to Go Long

Use Regeneron's Current Weakness to Go Long

Usually I prefer to buy strength as opposed to buying weakness, but I want to depart from my normal behavior with this biotech.

Prepare for Biotech Action Aplenty Today

As we await the jobs report, there is significant news across the biotech sector in the past 24 hours on some names I have mentioned in these pages. Amgen should be up nicely today after a judge stated that Regeneron would have to pull its PCKS9 inh...

Regeneron Cholesterol-Lowering Drug Banned From U.S. Market

Regeneron Cholesterol-Lowering Drug Banned From U.S. Market

A federal judge has banned the sale of Regeneron's cholesterol-lowering drug Praluent, handing a surprise and overwhelming victory to Amgen and its competing drug Repatha in a long-running patent lawsuit.

Cramer: Reviewing S&P's Hit-and-Miss Parade

Cramer: Reviewing S&P's Hit-and-Miss Parade

Even among the losers, buys are scarce.

Regeneron upgraded at BTIG

Ophthtech Shares Plunge as Drug Fails in Late Stage Trial

Ophthtech Shares Plunge as Drug Fails in Late Stage Trial

A drug made by Ophthotech failed in a late stage trial, sending shares of the stock plunging.

Cramer: With Trump, Everything's a Negotiation

Cramer: With Trump, Everything's a Negotiation

Just ask the drug companies or Boeing.

Cramer: We Are in Stage 2 of the Trump Love Affair With Business

Cramer: We Are in Stage 2 of the Trump Love Affair With Business

Hillary isn't the only one who seems to favor workers over capital. Trump does, too.